• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Respir Investig . Severity and prognosis of COVID-19 complicated by autoimmune pulmonary alveolar proteinosis

tetano

Editor, Senior Moderator
Respir Investig


. 2024 Nov 29;63(1):20-26.
doi: 10.1016/j.resinv.2024.11.008. Online ahead of print. Severity and prognosis of COVID-19 complicated by autoimmune pulmonary alveolar proteinosis

Toru Arai[SUP] 1 [/SUP], Yoshikazu Inoue[SUP] 2 [/SUP], Keiichi Akasaka[SUP] 3 [/SUP], Aiko Masunaga[SUP] 4 [/SUP], Masaki Fujita[SUP] 5 [/SUP], Etsuo Yamaguchi[SUP] 6 [/SUP], Mika Saigusa[SUP] 7 [/SUP], Koji Murakami[SUP] 8 [/SUP], Yu Kurahara[SUP] 9 [/SUP], Kazunari Tsuyuguchi[SUP] 9 [/SUP], Takuji Suzuki[SUP] 10 [/SUP], Yasunari Miyazaki[SUP] 11 [/SUP], Masashi Bando[SUP] 12 [/SUP], Takafumi Suda[SUP] 13 [/SUP]



Affiliations
Abstract

Background: The prognosis of patients with coronavirus disease 2019 (COVID-19) was poor although its survival rate has been improved after the occurrence of the Omicron strain. Autoimmune pulmonary alveolar proteinosis (APAP), a lung disease caused by macrophage dysfunction induced by anti-granulocyte-macrophage colony-stimulating factor (GM-CSF)-neutralizing autoantibodies, is characterized by the deposition of proteinaceous material in the alveolar spaces. The clinical course of COVID-19 in patients with APAP remains unclear and this study aimed to clarify it.
Methods: The data of 23 patients with APAP, who were diagnosed with COVID-19 between January 2020 and May 2023 and collected through a nationwide questionnaire surveillance system, were retrospectively reviewed.
Results: Based on the epidemiological frequency at disease onset, suspected strains of severe acute respiratory syndrome coronavirus 2 were Omicron (n = 18) and non-Omicron (n = 5). Fifteen patients were vaccinated. Six and three patients received anti-viral drugs and corticosteroids, respectively. One patient in the third trimester of pregnancy died despite treatment in the intensive care unit. Six patients were complicated by pneumonia and/or required supplemental oxygen. These patients were suspected to have non-Omicron strains (p = 0.087). Vaccination status showed a significant association with suspected Omicron strains. The radiological findings in four patients and shortness of breath improved in two of the four patients after COVID-19.
Conclusions: The severity and prognosis of the patients were not worse than those predicted based on the results of a previous study. The transition from a non-Omicron strain to an Omicron strain and the vaccination status may have affected these results.

Keywords: Autoimmune pulmonary alveolar proteinosis; Coronavirus disease 2019; Granulocyte-macrophage colony-stimulating factor; Severe acute respiratory syndrome coronavirus 2; Vaccination.

 
Back
Top Bottom